Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lanifibranor - Inventiva Pharma

Drug Profile

Lanifibranor - Inventiva Pharma

Alternative Names: IVA-337

Latest Information Update: 20 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inventiva Pharma
  • Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Antineoplastics; Benzothiazoles; Butyric acids; Halogenated hydrocarbons; Hepatoprotectants; Indoles; Skin disorder therapies; Small molecules; Sulfones
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Fibrosis; Non-alcoholic steatohepatitis
  • Phase II Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
  • Preclinical Liver cirrhosis
  • No development reported Bladder cancer
  • Discontinued Systemic scleroderma

Most Recent Events

  • 18 Mar 2024 Interim PD, efficacy and adverse events data from a phase II LEGEND trial in Non-alcoholic fatty liver disease and Type 2 diabetes mellitus released by Inventiva Pharma
  • 07 Mar 2024 Inventiva Pharma plans submission for potential accelerated approval to the US FDA and potential conditional approval to the EMA of lanifibranor for the treatment of Non-alcoholic steatohepatitis
  • 07 Mar 2024 Inventiva lifts the voluntary pause on screening and randomization of its NATiV3 phase III clinical trial in Non-alcoholic steatohepatitis and Fibrosis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top